Stock Track | GeneDx Holdings (WGS) Soars 5.58% as Q1 2025 Earnings Beat Expectations

Stock Track

May 02, 2025

Shares of GeneDx Holdings (NASDAQ: WGS) are soaring 5.58% in intraday trading on Friday, following the release of its impressive first-quarter 2025 financial results. The genetic testing company reported better-than-expected earnings and revenue figures, signaling strong growth and improved financial health.

GeneDx's Q1 2025 report showcased significant year-over-year improvements. The company's revenue surged 40% to $87.1 million, surpassing analyst estimates by 9.2%. Additionally, GeneDx's net loss narrowed by 68%, with the loss per share improving from $0.78 in Q1 2024 to $0.23 in Q1 2025, beating analyst expectations by 4.2%.

Investors appear encouraged by GeneDx's financial progress and future prospects. The company's revenue is forecast to grow at an average of 14% per annum over the next three years, outpacing the 7% growth projected for the US Healthcare industry. This positive outlook, combined with the strong Q1 performance, has likely fueled today's stock price surge, as the market reassesses GeneDx's potential in the competitive genetic testing landscape.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1118468982"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1118468982\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1118468982?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-02 22:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118468982","market":"us","top_or_hot":-1,"title":"Stock Track | GeneDx Holdings (WGS) Soars 5.58% as Q1 2025 Earnings Beat Expectations","media":"Stock Track","content":"<p>Shares of GeneDx Holdings (NASDAQ: WGS) are soaring 5.58% in intraday trading on Friday, following the release of its impressive first-quarter 2025 financial results. The genetic testing company reported better-than-expected earnings and revenue figures, signaling strong growth and improved financial health.</p>\n\n<p>GeneDx's Q1 2025 report showcased significant year-over-year improvements. The company's revenue surged 40% to $87.1 million, surpassing analyst estimates by 9.2%. Additionally, GeneDx's net loss narrowed by 68%, with the loss per share improving from $0.78 in Q1 2024 to $0.23 in Q1 2025, beating analyst expectations by 4.2%.</p>\n\n<p>Investors appear encouraged by GeneDx's financial progress and future prospects. The company's revenue is forecast to grow at an average of 14% per annum over the next three years, outpacing the 7% growth projected for the US Healthcare industry. This positive outlook, combined with the strong Q1 performance, has likely fueled today's stock price surge, as the market reassesses GeneDx's potential in the competitive genetic testing landscape.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | GeneDx Holdings (WGS) Soars 5.58% as Q1 2025 Earnings Beat Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | GeneDx Holdings (WGS) Soars 5.58% as Q1 2025 Earnings Beat Expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-05-02 22:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of GeneDx Holdings (NASDAQ: WGS) are soaring 5.58% in intraday trading on Friday, following the release of its impressive first-quarter 2025 financial results. The genetic testing company reported better-than-expected earnings and revenue figures, signaling strong growth and improved financial health.</p>\n\n<p>GeneDx's Q1 2025 report showcased significant year-over-year improvements. The company's revenue surged 40% to $87.1 million, surpassing analyst estimates by 9.2%. Additionally, GeneDx's net loss narrowed by 68%, with the loss per share improving from $0.78 in Q1 2024 to $0.23 in Q1 2025, beating analyst expectations by 4.2%.</p>\n\n<p>Investors appear encouraged by GeneDx's financial progress and future prospects. The company's revenue is forecast to grow at an average of 14% per annum over the next three years, outpacing the 7% growth projected for the US Healthcare industry. This positive outlook, combined with the strong Q1 performance, has likely fueled today's stock price surge, as the market reassesses GeneDx's potential in the competitive genetic testing landscape.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"WGS","symbol_name":"GeneDx Holdings","start_time":0,"source_url":"","article_id":"1118468982","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118468982","pubTimestamp":1746195267,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of GeneDx Holdings  are soaring 5.58% in intraday trading on Friday, following the release of its impressive first-quarter 2025 financial results. The genetic testing company reported better-than-expected earnings and revenue figures, signaling strong growth and improved financial health.GeneDx's Q1 2025 report showcased significant year-over-year improvements. The company's revenue surged 40% to $87.1 million, surpassing analyst estimates by 9.2%. Additionally, GeneDx's net loss narrowed","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"WGS":"GeneDx Holdings"},"translate_title":"股票轨迹GeneDx Holdings(WGS)因2025年第一季度盈利超出预期而飙升5.58%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WGS":1},"content_text":"Shares of GeneDx Holdings (NASDAQ: WGS) are soaring 5.58% in intraday trading on Friday, following the release of its impressive first-quarter 2025 financial results. The genetic testing company reported better-than-expected earnings and revenue figures, signaling strong growth and improved financial health.\nGeneDx's Q1 2025 report showcased significant year-over-year improvements. The company's revenue surged 40% to $87.1 million, surpassing analyst estimates by 9.2%. Additionally, GeneDx's net loss narrowed by 68%, with the loss per share improving from $0.78 in Q1 2024 to $0.23 in Q1 2025, beating analyst expectations by 4.2%.\nInvestors appear encouraged by GeneDx's financial progress and future prospects. The company's revenue is forecast to grow at an average of 14% per annum over the next three years, outpacing the 7% growth projected for the US Healthcare industry. This positive outlook, combined with the strong Q1 performance, has likely fueled today's stock price surge, as the market reassesses GeneDx's potential in the competitive genetic testing landscape.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}